Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections
- 31 January 2007
- journal article
- Published by Elsevier BV in International Journal of Antimicrobial Agents
- Vol. 29 (1), 62-65
- https://doi.org/10.1016/j.ijantimicag.2006.08.039
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in TurkeyJournal of Antimicrobial Chemotherapy, 2005
- Extended-spectrum β-lactamases: implications for the clinical microbiology laboratory, therapy, and infection controlJournal of Infection, 2003
- Why fosfomycin trometamol as first line therapy for uncomplicated UTI?International Journal of Antimicrobial Agents, 2003
- Short term therapy for uncomplicated urinary tract infection today. Clinical outcome upholds the theoriesInternational Journal of Antimicrobial Agents, 2003
- Antibiotic prescribing and urinary tract infectionInternational Journal of Antimicrobial Agents, 2002
- Transmissible fosfomycin resistance markers in urinary isolates and imported foodstuffs in the UK during 1994 and 1995.Journal of Antimicrobial Chemotherapy, 2001
- A comparison between single-dose fosfomycin trometamol (Monuril®) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in womenInternational Journal of Antimicrobial Agents, 1998
- Single-dose fosfomycin trometamol versus 5-day cephalexin regimen for treatment of uncomplicated lower urinary tract infections in womenAntimicrobial Agents and Chemotherapy, 1994
- Fosfomycin trometamol in a single dose versus seven days nitrofurantoin in the treatment of acute uncomplicated urinary tract infections in womenPharmacy World & Science, 1993
- Evaluation of New Anti-Infective Drugs for the Treatment of Urinary Tract InfectionClinical Infectious Diseases, 1992